Last reviewed · How we verify
UCB7665 Intravenous 5 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
UCB7665 Intravenous 5 (UCB7665 Intravenous 5) — UCB Celltech.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| UCB7665 Intravenous 5 TARGET | UCB7665 Intravenous 5 | UCB Celltech | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- UCB7665 Intravenous 5 CI watch — RSS
- UCB7665 Intravenous 5 CI watch — Atom
- UCB7665 Intravenous 5 CI watch — JSON
- UCB7665 Intravenous 5 alone — RSS
Cite this brief
Drug Landscape (2026). UCB7665 Intravenous 5 — Competitive Intelligence Brief. https://druglandscape.com/ci/ucb7665-intravenous-5. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab